| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pediatrics, Medical University of South Carolina, and
Department of Pathology, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29425
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins are newly identified immunomodulators. In vivo treatment of SJL/J mice with lovastatin reduced the duration and clinical severity of active and passive experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Lovastatin induced the expression of GATA3 and the phosphorylation of STAT6, whereas it inhibited tyrosine phosphorylation of Janus kinase 2, tyrosine kinase 2, and STAT4. Inhibition of the Janus kinase-STAT4 pathway by lovastatin modulated T0 to Th1 differentiation and reduced cytokine (IFN-
and TNF-
) production, thus inducing Th2 cytokines (IL-4, IL-5, and IL-10). It inhibited T-bet (T box transcription factor) and NF-
B in activated T cells and significantly reduced infiltration of CD4- and MHC class II-positive cells to CNS. Further, it stabilized IL-4 production and GATA-3 expression in differentiated Th2 cells, whereas in differentiated Th1 cells it inhibited the expression of T-bet and reduced the production of IFN-. Moreover, lovastatin-exposed macrophage and BV2 (microglia) in allogeneic MLRs induced the production of the anti-inflammatory cytokine IL-10. These observations indicate that the anti-inflammatory effects of lovastatin are mediated via T cells as well as APCs, because it modulates the polarization patterns of naive T cell activation in an APC-independent system. Together, these findings reveal that lovastatin may have possible therapeutic value involving new targets (in both APCs and T cells) for the treatment of multiple sclerosis and other inflammatory diseases.
This article has been cited by other articles:
|
|
 |
|
  X. Zhang, J. Jin, X. Peng, V. S. Ramgolam, and S. Markovic-Plese Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes J. Immunol., May 15, 2008; 180(10): 6988 - 6996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Andras, G. Rha, W. Huang, S. Eum, P.-O. Couraud, I. A. Romero, B. Hennig, and M. Toborek Simvastatin Protects against Amyloid {beta} and HIV-1 Tat-Induced Promoter Activities of Inflammatory Genes in Brain Endothelial Cells Mol. Pharmacol., May 1, 2008; 73(5): 1424 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Waiczies, I. Bendix, T. Prozorovski, M. Ratner, I. Nazarenko, C. F. Pfueller, A. U. Brandt, J. Herz, S. Brocke, O. Ullrich, et al. Geranylgeranylation but Not GTP Loading Determines Rho Migratory Function in T Cells J. Immunol., November 1, 2007; 179(9): 6024 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Lee, H. Qin, and E. N. Benveniste Simvastatin inhibits IFN-{gamma}-induced CD40 gene expression by suppressing STAT-1{alpha} J. Leukoc. Biol., August 1, 2007; 82(2): 436 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rossi, D. Padmanaban, J. Ni, L.-A. Yeh, M. A. Glicksman, and H. Waldner Identifying Druglike Inhibitors of Myelin-Reactive T Cells by Phenotypic High-Throughput Screening of a Small-Molecule Library J Biomol Screen, June 1, 2007; 12(4): 481 - 489. [Abstract] [PDF]
|
|
|
|
|
|
I. D'Alimonte, V. Flati, M. D'Auro, E. Toniato, S. Martinotti, M. P. Rathbone, S. Jiang, P. Ballerini, P. Di Iorio, F. Caciagli, et al. Guanosine Inhibits CD40 Receptor Expression and Function Induced by Cytokines and beta Amyloid in Mouse Microglia Cells J. Immunol., January 15, 2007; 178(2): 720 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-F. Fu, Y.-N. Zhu, J. Ni, X.-G. Zhong, W. Tang, Y.-D. Re, L.-P. Shi, J. Wan, Y.-F. Yang, C. Yuan, et al. A Reversible S-Adenosyl-L-Homocysteine Hydrolase Inhibitor Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting T Cell Activation J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 799 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aprahamian, R. Bonegio, J. Rizzo, H. Perlman, D. J. Lefer, I. R. Rifkin, and K. Walsh Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol., September 1, 2006; 177(5): 3028 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis Am. J. Pathol., September 1, 2006; 169(3): 1012 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arora, L. Chen, M. Paglia, I. Gallagher, J. E. Allen, Y. M. Vyas, A. Ray, and P. Ray Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells PNAS, May 16, 2006; 103(20): 7777 - 7782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Dunn, S. Youssef, M. J. Goldstein, T. Prod'homme, M. S. Weber, S. S. Zamvil, and L. Steinman Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J. Exp. Med., February 21, 2006; 203(2): 401 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rattan, S. Giri, A. K. Singh, and I. Singh 5-Aminoimidazole-4-carboxamide-1-{beta}-D-ribofuranoside Inhibits Cancer Cell Proliferation in Vitro and in Vivo via AMP-activated Protein Kinase J. Biol. Chem., November 25, 2005; 280(47): 39582 - 39593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cordle, J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth Mechanisms of Statin-mediated Inhibition of Small G-protein Function J. Biol. Chem., October 7, 2005; 280(40): 34202 - 34209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Riboldi, M Gerosa, and P L Meroni Statins and autoimmune diseases Lupus, September 1, 2005; 14(9): 765 - 768. [Abstract] [PDF]
|
|
|
|
 |
|
 A. S. Paintlia, M. K. Paintlia, M. Khan, T. Vollmer, A. K. Singh, and I. Singh HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis FASEB J, September 1, 2005; 19(11): 1407 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nath, S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh 5-Aminoimidazole-4-Carboxamide Ribonucleoside: A Novel Immunomodulator with Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis J. Immunol., July 1, 2005; 175(1): 566 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Gegg, R. Harry, D. Hankey, H. Zambarakji, G. Pryce, D. Baker, P. Adamson, V. Calder, and J. Greenwood Suppression of Autoimmune Retinal Disease by Lovastatin Does Not Require Th2 Cytokine Induction J. Immunol., February 15, 2005; 174(4): 2327 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bucca, A. Marsico, E. Panaro, P. Bigo, and L. Brussino Statins and Nasal Polyps Ann Intern Med, February 15, 2005; 142(4): 310 - 311. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cordle and G. Landreth 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate {beta}-Amyloid-Induced Microglial Inflammatory Responses J. Neurosci., January 12, 2005; 25(2): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
